In this issue:
- Prevalence of DXA in Australian men with prostate cancer commencing ADT
- Impact of PPI use on ICI response in cancer patients
- Chemotherapy vs. pembrolizumab ± concomitant PPI in urothelial cancer
- Recurrence predictors following surgery for renal cell carcinoma with tumour thrombus
- Management strategies/outcomes for a renal mass in a solitary kidney
- Nivolumab in renal cell carcinoma with bone metastases
- Survival and recurrence in mNSGCT after clinical response with first-line chemotherapy and intermediate/poor prognosis
- Second-line nivolumab vs. axitinib in metastatic renal cell carcinoma
- Long-term safety and efficacy of pembrolizumab in metastatic urothelial carcinoma
- Rucaparib vs. physician’s choice in metastatic prostate cancer
- Temporary treatment cessation vs. treatment continuation in advanced clear cell renal cell carcinoma
- Lenvatinib + pembrolizumab vs. sunitinib in advanced renal cell carcinoma
Please login below to download this issue (PDF)